How to Buy Ars Pharmaceuticals Stock
Ars Pharmaceuticals Inc
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites.
Ars Pharmaceuticals stock last closed at $14.32, down 3.76% from the previous day, and has increased 74.42% in one year. It has overperformed other stocks in the Biotechnology industry by 1.52 percentage points. Ars Pharmaceuticals stock is currently +89.67% from its 52-week low of $7.55, and -22.64% from its 52-week high of $18.51.
There are currently 98.12M SPRY shares outstanding. The market value of SPRY is $1.41B. In the past 24 hours, 2.46M SPRY shares were traded.
How to Buy Ars Pharmaceuticals Stock
Not sure how to invest in Ars Pharmaceuticals stock? Here's how.
- Choose where to buy Ars Pharmaceuticals stock: You need to choose a stock brokerage, but don't worry - we've researched dozens of online stock brokerages and apps to help you decide where to buy Ars Pharmaceuticals stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Fund your investment account: Choose your method of payment and add your details.
- Research Ars Pharmaceuticals stock: The Ars Pharmaceuticals ticker symbol is SPRY. Is Ars Pharmaceuticals stock a good investment? Should you buy shares of SPRY? How do SPRY's underlying business fundamentals look? Do top analysts think Ars Pharmaceuticals is a good buy? Why has SPRY's stock price moved recently? (Hint: Our stock research tools can help you understand if SPRY is a good stock to buy).
- Make your SPRY purchase: Decide if you will purchase SPRY shares at the current market price or use a limit order to buy SPRY shares at a given price.
- Keep tabs on your investment in SPRY: Create a watchlist to get the latest news on your position in Ars Pharmaceuticals stock.
Step 1: Choose where to buy Ars Pharmaceuticals stock
You will need a brokerage account to access the NASDAQ market and buy SPRY stock.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best stock brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world markets: From Technology to Real Estate, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected the right brokerage, it's time to fill out some personal information so you are able to buy SPRY stock today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to open your new trading account.
- Submit your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you've opened your account on the highest rated app to buy and sell stocks, your next step is to transfer the money for your investment:
Check out the video below if you need help transferring money into your new brokerage account.
Step 4: Research Ars Pharmaceuticals stock
Once you have chosen the best place to buy Ars Pharmaceuticals stock, it's absolutely critical to analyze their stock before you buy, so you actually wrap your head around the risk and upside.
Ars Pharmaceuticals shares quick numbers
SPRY Due Diligence Score
WallStreetZen was designed to help average investors do more in-depth fundamental analysis in less time.
You can see all of the due diligence checks on SPRY's stock page.
How is SPRY stock valued?
You can use many financial metrics, analyses, models, and charts to gauge SPRY's true value.
Using relative valuations ratios:
- SPRY could be undervalued based on its P/E ratio of 179x, relative to Biotechnology industry P/E ratio of -184.27x
- SPRY could be overvalued based on its P/B ratio of 5.47x, relative to Biotechnology industry P/B ratio of 4.04x
- SPRY could be overvalued based on its PEG ratio of 3.15x
You can do additional valuation research on SPRY's stock here.
SPRY Financial Summary
Passed Financial Due Diligence Checks:
- SPRY profit margin has gone up from -181,216.7% to 9% in the past year.
- SPRY earnings of $8.29M is not enough to cover its interest payments.
- Total SPRY debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the SPRY balance sheet.
- There are more short-term assets than long-term liabilities on the SPRY balance sheet.
- SPRY has a low debt to equity ratio of 0.37.
Failed Financial Due Diligence Checks:
- SPRY's operating cash flow of $13.55M allows it to safely service it's debt of $69.43M.
Do analysts think it's a good time to buy Ars Pharmaceuticals stock
Out of 3 Wall Street analysts who research SPRY, the consensus analyst rating on Ars Pharmaceuticals is a Strong Buy
It's important to keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
You can dig deeper into what analysts are saying on the Ars Pharmaceuticals stock forecast page.
SPRY Technicals
SPRY Growth Numbers
Last year, SPRY revenue was $89.15M. In the last 3 year, SPRY's revenue has increased by 247.66% per year. This was faster than the Biotechnology industry average of 44.31%.
Dig into SPRY's earnings and revenue performance here.
Who is buying/selling SPRY?
Over the last year, executives and large shareholders at SPRY have sold more shares than they have bought.
Laura Shawver, Director of SPRY, was the latest SPRY insider to buy. They bought $109,168.65 worth of SPRY shares on Apr 7, 2025.
Get more info about who owns SPRY shares here.
Does SPRY stock generate passive income?
No, Ars Pharmaceuticals doesn't provide an income stream by paying out dividends.
What do other investors have to say about SPRY?
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Make your SPRY purchase
You have two primary order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are generally sufficient. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a particular price, use a limit order.
Press the Open Trade button and eToro will place your order.
If you need additional assistance buying stocks on eToro, click the how to video below:
Step 6: Keep tabs on your investment in SPRY
Now that you own some shares in SPRY, you'll want to stay up-to-date on your company.
Make a watchlist to get notified of the latest news about your SPRY stock.
SPRY Feed
How to Buy Stock in Ars Pharmaceuticals
To reiterate, here are the 6 steps for buying Ars Pharmaceuticals stock:
- Choose where to buy Ars Pharmaceuticals stock
- Open your brokerage account
- Fund your investment account
- Research Ars Pharmaceuticals stock
- Make your SPRY purchase
- Keep tabs on your investment in SPRY
If you are looking for a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to monitor your investment in Ars Pharmaceuticals, create your watchlist below.
Trending Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.